CO2022005949A2 - Métodos para tratar pénfigo mediante la administración de (r)-2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enonitrilo - Google Patents
Métodos para tratar pénfigo mediante la administración de (r)-2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enonitriloInfo
- Publication number
- CO2022005949A2 CO2022005949A2 CONC2022/0005949A CO2022005949A CO2022005949A2 CO 2022005949 A2 CO2022005949 A2 CO 2022005949A2 CO 2022005949 A CO2022005949 A CO 2022005949A CO 2022005949 A2 CO2022005949 A2 CO 2022005949A2
- Authority
- CO
- Colombia
- Prior art keywords
- enenitrile
- oxetan
- pent
- pyrazolo
- piperazin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962913029P | 2019-10-09 | 2019-10-09 | |
| US201962942877P | 2019-12-03 | 2019-12-03 | |
| PCT/US2020/054809 WO2021072095A1 (en) | 2019-10-09 | 2020-10-08 | Methods of treating pemphigus by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022005949A2 true CO2022005949A2 (es) | 2022-07-29 |
Family
ID=73030241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0005949A CO2022005949A2 (es) | 2019-10-09 | 2022-05-06 | Métodos para tratar pénfigo mediante la administración de (r)-2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enonitrilo |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20210106583A1 (https=) |
| EP (1) | EP4041240A1 (https=) |
| JP (2) | JP7784995B2 (https=) |
| KR (1) | KR20220079909A (https=) |
| CN (1) | CN115190798A (https=) |
| AU (1) | AU2020363873A1 (https=) |
| BR (1) | BR112022005575A2 (https=) |
| CA (1) | CA3153750A1 (https=) |
| CO (1) | CO2022005949A2 (https=) |
| IL (1) | IL291726A (https=) |
| MX (1) | MX2022004283A (https=) |
| WO (1) | WO2021072095A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202535403A (zh) * | 2023-10-25 | 2025-09-16 | 美商普林斯匹亞生物製藥公司 | 藉由投予（ｒ）－２－［３－［４－胺基－３－（２－氟－４－苯氧基－苯基）吡唑並［３，４－ｄ］嘧啶－１－基］哌啶－１－羰基］－４－甲基－４－［４－（氧雜環丁烷－３－基）哌𠯤－１－基］戊－２－烯腈治療慢性自發性蕁麻疹 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME03455B (me) | 2012-09-10 | 2020-01-20 | Principia Biopharma Inc | Jedinjenja pirazolopirimidina kao inhibitori kinaze |
| PT3107544T (pt) | 2014-02-21 | 2021-01-05 | Principia Biopharma Inc | Sais e forma sólida de um inibidor de btk |
| US10485797B2 (en) | 2014-12-18 | 2019-11-26 | Principia Biopharma Inc. | Treatment of pemphigus |
| CA2971109C (en) | 2014-12-24 | 2024-07-02 | Principia Biopharma Inc. | SITE-SPECIFIC DOSAGE OF A BTK INHIBITOR |
| MA45547A (fr) | 2016-06-29 | 2019-05-08 | Principia Biopharma Inc | Formulations à libération modifiée à base de 2-[3-[4-amino-3-(2-fluoro-4-phénoxy-phényl)pyrazolo[3,4-d]pyrimidine-1-yl]pipéridine-1-carbonyl]-4-méthyl-4-[4-(oxétane-3-yl)pipérazine-1-yl]pent-2-ènenitrile |
| WO2019208805A1 (ja) * | 2018-04-27 | 2019-10-31 | 小野薬品工業株式会社 | Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤 |
-
2020
- 2020-10-08 US US17/066,300 patent/US20210106583A1/en not_active Abandoned
- 2020-10-08 BR BR112022005575A patent/BR112022005575A2/pt unknown
- 2020-10-08 EP EP20797943.6A patent/EP4041240A1/en active Pending
- 2020-10-08 AU AU2020363873A patent/AU2020363873A1/en active Pending
- 2020-10-08 WO PCT/US2020/054809 patent/WO2021072095A1/en not_active Ceased
- 2020-10-08 CA CA3153750A patent/CA3153750A1/en active Pending
- 2020-10-08 JP JP2022520968A patent/JP7784995B2/ja active Active
- 2020-10-08 MX MX2022004283A patent/MX2022004283A/es unknown
- 2020-10-08 CN CN202080083113.6A patent/CN115190798A/zh active Pending
- 2020-10-08 KR KR1020227015113A patent/KR20220079909A/ko active Pending
-
2022
- 2022-03-27 IL IL291726A patent/IL291726A/en unknown
- 2022-05-06 CO CONC2022/0005949A patent/CO2022005949A2/es unknown
- 2022-09-30 US US17/957,073 patent/US20230158033A1/en active Pending
-
2025
- 2025-07-18 JP JP2025120944A patent/JP2025157438A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025157438A (ja) | 2025-10-15 |
| BR112022005575A2 (pt) | 2022-06-21 |
| IL291726A (en) | 2022-05-01 |
| JP2022552199A (ja) | 2022-12-15 |
| MX2022004283A (es) | 2022-07-12 |
| WO2021072095A1 (en) | 2021-04-15 |
| CA3153750A1 (en) | 2021-04-15 |
| US20230158033A1 (en) | 2023-05-25 |
| EP4041240A1 (en) | 2022-08-17 |
| KR20220079909A (ko) | 2022-06-14 |
| TW202128172A (zh) | 2021-08-01 |
| AU2020363873A1 (en) | 2022-04-14 |
| US20210106583A1 (en) | 2021-04-15 |
| JP7784995B2 (ja) | 2025-12-12 |
| CN115190798A (zh) | 2022-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Murphy et al. | Advances in supportive care for late effects of head and neck cancer | |
| CY1123110T1 (el) | Συνδυασμοι και τροποι χορηγησης θεραπευτικων παραγοντων και θεραπεια συνδυασμου | |
| AR050418A1 (es) | Dosificacion fija de anticuerpos her | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| CY1114215T1 (el) | Φαρμακευτικες συνθεσεις διαλυματος για υπο πιεση εισπνευστηρες μετρουμενης δοσης | |
| AR089862A1 (es) | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA | |
| CY1111595T1 (el) | Τροποποιηση της θεραπειας με πιρφενιδονη για ασθενεις με μη φυσιολογικη ηπατικη λειτουργια | |
| CY1116215T1 (el) | Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης | |
| CL2020003101A1 (es) | Sales de sepiapterina farmacéuticamente aceptables. | |
| ECSP045140A (es) | Formulaciones farmacéuticas derivadas del platino | |
| MX2017000628A (es) | Metodos para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia. | |
| EA202092154A1 (ru) | Комбинированная терапия | |
| BR112021025764A2 (pt) | Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo | |
| Uchida et al. | The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets | |
| UY38948A (es) | Régimen de dosificación para agentes anti-dll3 | |
| Gregoire et al. | Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double-blind, placebo-controlled study | |
| MX2021014161A (es) | Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton. | |
| EA202090242A1 (ru) | Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов | |
| MX390667B (es) | Dosis y regimen para un inhibidor de la interaccion de hdm2-p53 en tumores hematologicos. | |
| MX2021011746A (es) | Formulacion de combinacion triple de dosis baja. | |
| MX2019005104A (es) | Composiciones de zinc-y-pga y métodos para tratar el cancer. | |
| CO2022005949A2 (es) | Métodos para tratar pénfigo mediante la administración de (r)-2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enonitrilo | |
| EA202190334A1 (ru) | Фармацевтическая лекарственная форма для перорального введения с модифицированным высвобождением | |
| AR114306A1 (es) | Tratamiento y prevención de trastornos del sueño | |
| CR20220127A (es) | Administración de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1 |